Chimerix Inc (NASDAQ:CMRX), a sought after biopharmaceutical company active in the production of novel antiviral to cure diseases that need unmet medical attention, announced results of Phase III trials of Brincidofovir.
As per the reports, the top-line results show that the trials in the hematopoietic cell transplantation patients didn’t achieve their endpoint.
Insights of The Matter
These tests were intended to prevent CMV (clinically significant cytomegalovirus) infection through week twenty-four post transplant. However, the results unveiled that fewer patients showed CMV infection signs in their brincidofovir arm through week 14 as compared to Phase two study. Between the week 14 and week 24, researchers found an increased rate of CMV infection in the brincidofovir arm as compared to the control arm.
Initial analysis of these results clarifies that the failure of the primary endpoint of mortality in the brincidofovir arm and CMV infections occurred due to confirmed cases of graft-versus-host-disease. As a consequence of this disease, the use of corticosteroids increases a lot more than the control arm. Researchers found that the rate of study drug discontinuation in the case of gastrointestinal events was 10% lesser than that which was observed in the Phase II trial in a similar HCT population.
Management Call
The senior management team of Chimerix is pleased to report these results and hopes that trial results will continue to improve with the passage of time. According to M. Michelle Berrey, CEO & President, Chimerix, the results of Phase III trials aren’t excited at all for the company. The management team was expected better results, but nothing like that happened.
Going forward, Chimerix will increase its efforts to find out potential growth path related to brincidofovir.
He further added that there is no dearth of cash, experience and time; therefore, Chimerix Inc (NASDAQ:CMRX) will continue to seek for new ways that can lead to the development of brincidofovir in the future. It will keep abreast all the investors about the future growth of the company.
